Ab0458 Deucravacitinib, a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Active Psa: Assessment of Direct and Indirect Impact on Pain and Fatigue Outcomes by Mediation Analysis in a Phase 2 Clinical Trial